Xolair 150 mg solution for injection in pre-filled syringe, Placebo, solution for injection in pre-filled syringe, BP11 clinical trials

A Phase 3, Randomized, Double-Blind, Parallel Group, Multicentre Study to Compare Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, immunogenicity, of BP11 versus EU-Approved Xolair in patients With Chronic Spontaneous Urticaria Who Are Resistant to H1 Antagonist.

This study compares a new medicine (BP11) with an approved one (Xolair) for chronic hives that haven't responded to usual treatments. Researchers want to see if BP11 is safe and effective in reducing itching and other symptoms.